Blog
RSS FeedPosted by Michael Wonder on 23 Jul 2020
CADTH publishes final recommendation for Mayzent
23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...
Posted by Michael Wonder on 20 Jul 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...
Posted by Michael Wonder on 20 Jul 2020
CADTH publishes final recommendation for Stelara
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...
Posted by Michael Wonder on 14 Jul 2020
Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...
Posted by Michael Wonder on 25 Jun 2020
Consultation on CADTH’s drug reimbursement review procedures
25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian ...
Posted by Michael Wonder on 03 Jun 2020
CADTH publishes final recommendation for Crysvita
1 June 2020 - CADTH has completed its assessment of burosumab for the treatment of patients with X-linked hypophosphatemia. ...
Posted by Michael Wonder on 25 May 2020
CADTH sees green for Beovu
25 May 2020 - CADTH has published its final recommendation for Novartis' Beovu. ...
Posted by Michael Wonder on 21 May 2020
CADTH posts final recommendation for Entyvio
21 May 2020 - CADTH has completed its consideration of subcutaneous vedolizumab for the treatment of adult patients with moderately to ...
Posted by Michael Wonder on 19 May 2020
CADTH Board of Directors names Suzanne McGurn as next President and CEO
19 May 2020 - The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next ...
Posted by Michael Wonder on 15 May 2020
The new definition of health technology assessment: a milestone in international collaboration
15 May 2020 - An international joint task group co-led by the International Network of Agencies for Health Technology Assessment and ...
Posted by Michael Wonder on 29 Apr 2020
Updated fees for CADTH Pharmaceutical Reviews
29 April 2020 - CADTH has updated the Fee Schedule for CADTH Pharmaceutical Reviews. ...
Posted by Michael Wonder on 08 Apr 2020
CADTH and COVID-19
8 April 2020 - If you’re looking for credible answers to your COVID-19 questions, we can help. ...
Posted by Michael Wonder on 18 Mar 2020
COVID-19: an update from Dr. Brian O’Rourke, CADTH President and CEO
18 March 2020 - As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the ...
Posted by Michael Wonder on 04 Mar 2020
Revised procedure for the sponsor review of initial CADTH pCODR reports
4 March 2020 - Initial CADTH pCODR reports will now be issued to the sponsor four business days before the target ...
Posted by Michael Wonder on 18 Feb 2020
CEADM applauds CADTH's decision to recommend an innovative depression medication for publicly-funded drug plans in Canada
18 February 2020 - Canadians for Equal Access to Depression Medication (CEADM) applauds the CADTH's recent decision recommending that the ...